PATENT CLAIM ANALYSIS

Application Number: 16060517
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "288000"]

Abstract:
The present invention relates to a use of type-2 dopaminergic receptor agonists in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), particularly in treatment or prevention of diseases of an eye retina resulting from an increase in permeability of blood vessels and their angiogenesis using cabergoline, a dopaminergic D2 receptor agonist.

Claim (Index 2):
The use according to  claim 1 , wherein the eye disease is a disease of an eye retina caused by an increase in permeability of blood vessels and/or their angiogenesis.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 94.0
- Lexical Diversity: 1.34043
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15058938', '15602096', '12457478', '12455958', '15307284']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6910036997827613
- 35 USC 102 Novelty (BERT): 0.5079369433433834
- Combined Prediction Score: 0.6726970241388236
- Mean Citation Score: 240.561512
- Max Citation Score: 258.2963
- Similarity Product: 182.16020809984207

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test